Valuation: Ocugen, Inc.

Capitalization 38Cr 33Cr 31Cr 29Cr 53Cr 3.47TCr 58Cr 355.52Cr 138.14Cr 1.64TCr 144.16Cr 141.1Cr 5.96TCr P/E ratio 2025 *
-5.39x
P/E ratio 2026 * -5.21x
Enterprise value 38Cr 33Cr 31Cr 29Cr 53Cr 3.47TCr 58Cr 355.52Cr 138.14Cr 1.64TCr 144.16Cr 141.1Cr 5.96TCr EV / Sales 2025 *
71.1x
EV / Sales 2026 * 125x
Free-Float
98.55%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+5.69%
1 week+4.84%
Current month+4.84%
1 month-2.26%
3 months+21.50%
6 months+12.07%
Current year+61.49%
More quotes
1 week 1.18
Extreme 1.18
1.32
1 month 1.09
Extreme 1.09
1.35
Current year 0.52
Extreme 0.515
1.9
1 year 0.52
Extreme 0.515
1.9
3 years 0.34
Extreme 0.345
2.1
5 years 0.29
Extreme 0.2856
18.77
10 years 0.17
Extreme 0.17
18.77
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 27/09/2019
Director of Finance/CFO 56 14/11/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 61 27/09/2019
Director/Board Member 58 01/09/2013
Director/Board Member 58 01/09/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+5.69%+4.84%+49.43%-11.56% 38Cr
-2.53%-5.31%+0.19%+14.63% 4.7TCr
+1.37%+0.47%+12.39%+6.02% 3.8TCr
-0.57%-3.19%+74.01%+57.04% 3.57TCr
+0.54%+1.85%+11.96%+17.47% 2.76TCr
+0.96%+3.92%+65.78%+167.94% 1.58TCr
+0.81%+0.04%+69.09%+229.87% 1.51TCr
+2.19%+2.24%-10.49%-3.62% 1.42TCr
-1.61%-3.24%+71.01% - 1.34TCr
+0.65%-3.26%+108.32%+106.85% 1.27TCr
Average +0.78%-1.30%+45.17%+64.96% 2.2TCr
Weighted average by Cap. -0.09%-1.89%+35.16%+52.56%
See all sector performances

Financials

2025 *2026 *
Net sales 54.04L 45.97L 42.92L 40.27L 74.46L 49Cr 81.06L 5Cr 1.94Cr 23Cr 2.03Cr 1.98Cr 84Cr 30.8L 26.2L 24.47L 22.95L 42.44L 28Cr 46.21L 2.85Cr 1.11Cr 13Cr 1.16Cr 1.13Cr 48Cr
Net income -6.93Cr -5.9Cr -5.5Cr -5.16Cr -9.55Cr -624.98Cr -10Cr -64Cr -25Cr -295.23Cr -26Cr -25Cr -1.08TCr -7.97Cr -6.78Cr -6.33Cr -5.94Cr -11Cr -719.05Cr -12Cr -74Cr -29Cr -339.68Cr -30Cr -29Cr -1.24TCr
Net Debt - -
More financial data * Estimated data
Logo Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Employees
95
More about the company
Date Price Change Volume
12/25/12 1.300 $ +5.69% 39,84,514
10/25/10 1.230 $ +1.65% 31,77,314
09/25/09 1.210 $ +0.83% 25,97,847
08/25/08 1.200 $ -1.64% 26,93,234
05/25/05 1.220 $ -1.61% 23,61,049

Delayed Quote Nasdaq, December 12, 2025 at 02:30 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.230USD
Average target price
9.000USD
Spread / Average Target
+631.71%
Consensus

Quarterly revenue - Rate of surprise